Netupitant/palonosetron is effective for preventing chemotherapy-induced nausea and vomiting in high-dose melphalan conditioning before autologous stem cell transplantation: A real-world analysis. [PDF]
Blood SciCao LQ +15 more
europepmc +1 more source
Olanzapine Use and Vomiting Incidence in Chemotherapy-receiving Patients With Cervical Cancer: Multicenter Post Hoc Analysis. [PDF]
In VivoKawamura Y +17 more
europepmc +1 more source
Prophylaxis and treatment of postoperative nausea and vomiting. [PDF]
BJA EducKovac A, Choksi N.
europepmc +1 more source
Investigating the effects of olanzapine on appetite and weight in patients with cancer in a systematic review. [PDF]
Discov OncolRenaux Torres MC +12 more
europepmc +1 more source
Palonosetron, a 5-HT3 Receptor Antagonist, Induces G1 Cell Cycle Arrest and Autophagy in Gastric Cancer Cells. [PDF]
Int J Mol SciYoo YC +5 more
europepmc +1 more source
Impact of antiemetic prophylaxis on reducing trastuzumab deruxtecan dose modifications in HER2+/HER2-low breast cancer. [PDF]
Future OncolShin J, Kim JY, Ahn HK, Ahn JS, Park YH.
europepmc +1 more source
Efficacy and Safety of Oral NEPA Versus Fosaprepitant Plus Palonosetron for Preventing Chemotherapy-Induced Nausea and Vomiting in Patients with Nasopharyngeal Carcinoma: A Propensity-Score-Matched Retrospective Study. [PDF]
Cancers (Basel)Cai Y +7 more
europepmc +1 more source
Postoperative nausea and vomiting: current concepts, management strategies, and future perspectives. [PDF]
Front PharmacolQiu L +3 more
europepmc +1 more source